$CLMT

Sajkowski Daniel J sold $153K of CLMT

Sajkowski Daniel J sold 4,240 shares of Calumet, Inc. /DE (CLMT) at $36.16 ($0.15M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sajkowski Daniel J
Published Jul 2, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLMT
Neutral
medium confidence
Mentioned
$CLMT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

The disclosure confirms an open-market sale by a director executed under a pre-arranged 10b5-1 plan; it does not provide new operating, financial, or regulatory information.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to drive price without additional company-specific catalysts.

03

What to watch

Insider sales are common and often tax/portfolio-driven; without context on total insider activity or concurrent company news, signal quality is low.

Relevance 3/10Novelty 5/10Timing: Filed 2026-07-02; sale executed 2026-07-01.

Background

SEC Form 4 reports an insider transaction for Calumet, Inc. (CLMT).

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Calumet, Inc. insider Daniel J. Sajkowski sold 4,240 shares on 2026-07-01 under a pre-arranged 10b5-1 plan for ~$153.3K.

Expected impact

Low near-term impact; any reaction is likely muted unless paired with other negative company news.

Evidence & confidence

The filing is a Form 4 sale (not a buy), but it specifies a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

None—single-company insider transaction with no sector-wide datapoint.

None.

None.

Counterpoint

A 10b5-1 sale can still coincide with insider expectations of near-term risk, but the plan structure usually limits the informational edge.

Key entities

  • Calumet, Inc.

    Subject of the Form 4 insider transaction; ticker CLMT.

  • Daniel J. Sajkowski

    Director who sold 4,240 shares on 2026-07-01 under a 10b5-1 plan.

Related articles

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.

$CLMTMed

Why Calumet Stock Was a Major Winner on Wednesday

Calumet (CLMT) shares rose more than 4% after the company said two wholly owned subsidiaries will redeem $100 million of senior notes due 2028, paying about 102.4% of par. Calumet also noted it reduced borrowings on its revolving credit facility in Q2, as part of a deleveraging plan.